Mechanisms of resistance to EZH2 inhibitors in diffuse large B-cell lymphomas-Reference-Cited by-同舟云学术

Mechanisms of resistance to EZH2 inhibitors in diffuse large B-cell lymphomas

Published:2018-05-10 Issue:19 Volume:131 Page:2125-2137
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Bisserier Malik¹,Wajapeyee Narendra¹^ORCID

Affiliation:

1. Department of Pathology, School of Medicine, Yale University, New Haven, CT

Abstract

Key Points Resistance to EZH2 inhibitors occurs due to the activation of survival pathways and acquired EZH2 mutations that prevent drug binding. Resistance mechanisms for different EZH2 inhibitors varies. Thus, cells resistant to 1 EZH2 inhibitor are sensitive to other inhibitors.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/131/19/2125/1468449/blood804344.pdf

Reference42 articles.

1. Timeline: chemotherapy and the war on cancer;Chabner;Nat Rev Cancer,2005

2. Targeted cancer therapy;Sawyers;Nature,2004

3. Cancer drug resistance: an evolving paradigm;Holohan;Nat Rev Cancer,2013

4. Combine and conquer: challenges for targeted therapy combinations in early phase trials;Lopez;Nat Rev Clin Oncol,2017

5. Molecular mechanisms of drug resistance;Longley;J Pathol,2005

Cited by 104 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Integrated pan-cancer analysis and experimental verification of the roles of meiotic nuclear divisions 1 in breast cancer;Biochemical and Biophysical Research Communications;2024-12

2. The Cell Cycle: a Key to Unlock EZH2-targeted Therapy Resistance;Cancer Discovery;2024-06-03

3. Overcoming Clinical Resistance to EZH2 Inhibition Using Rational Epigenetic Combination Therapy;Cancer Discovery;2024-06-03

4. Design, synthesis and activity evaluation of quinolinone derivatives as EZH2 inhibitors;Bioorganic & Medicinal Chemistry Letters;2024-06

5. Advances in proteomics in diffuse large B‑cell lymphoma (Review);Oncology Reports;2024-05-09